Zobrazeno 1 - 10
of 533
pro vyhledávání: '"Hypercalcemia of malignancy"'
Autor:
Lea Jessica Albrecht, Viktor Grünwald, Jürgen C. Becker, Ralf Gutzmer, Livia Asan, Ellen Uslar, Alexandra Eilers, Anne-Christine Müseler, Alexander Roesch, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone
Publikováno v:
EJC Skin Cancer, Vol 2, Iss , Pp 100261- (2024)
Introduction: Paraneoplastic hypercalcemia is a life-threatening complication and is usually caused by tumoral secretion of parathyroid hormone-related peptide (PTHrP). Endocrinopathies are common adverse events of immune checkpoint inhibitor (ICI) t
Externí odkaz:
https://doaj.org/article/8f76da47c470484490ffa38b95e0d931
Publikováno v:
JCRPE, Vol 16, Iss 2, Pp 224-228 (2024)
Severe hypercalcemia associated with vitamin D intoxication or malignancy in children is a rare and life-threatening condition. There is little published experience with Zoledronic acid (ZA) in the treatment of pediatric severe hypercalcemia. Here, w
Externí odkaz:
https://doaj.org/article/a9d454b66a6c49b2aa0ab13779ce33c5
Autor:
Sakina Hashizume, Masafumi Shimoda, Tetsuhiro Yoshinami, Kaori Abe, Nanae Masunaga, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Background Since humoral hypercalcemia of malignancy (HHM) in breast cancer patients without bone metastasis is rare, the clinical features of this condition are not fully understood. Case presentation During the recent 12 years, 3602 patien
Externí odkaz:
https://doaj.org/article/99f8a25b55544e639cc9a37f0bfcc515
Autor:
Azeez Farooki
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Hypercalcemia of malignancy (HCM) is a common clinical problem that is associated with considerable morbidity and negative effects on quality of life. Despite the availability of effective medical treatments for HCM, options are needed for cases that
Externí odkaz:
https://doaj.org/article/5de70f6c7bfd44a1af59430770b441c6
Publikováno v:
In Clinical Biochemistry July-August 2022 105-106:75-80
Autor:
Jeffrey M. Kroopnick, MD, Ubaldo Martinez-Outschoorn, MD, Madalina Tuluc, MD, PhD, Caroline S. Kim, MD
Publikováno v:
AACE Clinical Case Reports, Vol 7, Iss 3, Pp 200-203 (2021)
Introduction: Hypercalcemia of malignancy (HCM) portends a very poor prognosis, and no established guidelines exist regarding its management. Most instances of HCM are due to local osteolysis or secretion of parathyroid hormone related-peptide, while
Externí odkaz:
https://doaj.org/article/307762e082554052b5a0cec0489c30a3
Autor:
Chakhtoura, Marlene, El-Hajj Fuleihan, Ghada ∗
Publikováno v:
In Endocrinology and Metabolism Clinics of North America December 2021 50(4):781-792
Publikováno v:
Journal of Clinical and Translational Endocrinology Case Reports, Vol 26, Iss , Pp 100136- (2022)
Background/objective: To report a rare case of ectopic parathyroid hormone (PTH) secretion from poorly-differentiated adenocarcinoma and the lessons learned in management. Case report: A 54-year-old woman presented with fatigue, hip pain, and confusi
Externí odkaz:
https://doaj.org/article/39a860c793b446f69c2cf1c1cf644b79
Publikováno v:
Journal of Clinical and Translational Endocrinology Case Reports, Vol 26, Iss , Pp 100126- (2022)
Background: Hypercalcemia of malignancy (HCM), a PTH-independent process, usually occurs in solid tumors, multiple myeloma, and occasionally lymphomas. It generally results from excess secretion of parathyroid hormone related protein (PTHrP) by the t
Externí odkaz:
https://doaj.org/article/d8df2e8841f847f2b0282998718aba97